The TherapeuticsMD Inc (NASDAQ: TXMD) stock ended the week on Friday with notable gains after the company received a considerable boost from regulators.
The company announced on Friday that one of its treatments has been given coveted approval in two different regions of Europe. The treatment in question is Bijuve and it is an HRT compound that is targeted at females who suffer from symptoms of vasomotor. The approval from the authorities will now allow TherapeuticsMD to sell the product in Belgium and also in the United Kingdom.
Back in 2019, the company had also tied up a licensing agreement with Theramax and by virtue of that agreement, it can bring Bijuve to Europe. It is important to note that this agreement in question covers all markets except the ones in Israel, the United States, and Canada. Now that the product has been approved in Europe, TherapeuticsMD will get a milestone foot from Theramax.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.